Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
PLXPQ similar filings
- 12 Jun 17 PLx Pharma Inc. Announces Pricing of Registered Direct Offering
- 5 May 17 Regulation FD Disclosure
- 2 May 17 Rita M. O’Connor Appointed Chief Financial Officer of PLx Pharma
- 20 Apr 17 PLx Pharma and Dipexium Pharmaceuticals Complete Merger
- 22 Dec 16 Dipexium and PLx Pharma Announce Merger Agreement
- 14 Dec 16 Departure of Directors or Certain Officers
- 16 Nov 16 Departure of Directors or Certain Officers
Filing view
External links
Exhibit 16.1
April 19, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read the statements made by PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) dated April 19, 2017. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ CohnReznick LLP